2024
Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic
Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Obstetrical & Gynecological Survey 2024, 79: 643-644. DOI: 10.1097/01.ogx.0001095056.57063.30.Peer-Reviewed Original ResearchThrombotic thrombocytopenic purpuraFamily planning clinicsReproductive-age womenHerbal supplementsOral contraceptivesThrombocytopenic purpuraAdverse eventsPlanning clinicsDrug interactionsSupplement useCardiac arrhythmiasHerbal supplement useDepression medicationPrescription medicationsDrugGastrointestinal illnessMedicationRisk associated with interactionsSupplementationPurpuraContraceptionArrhythmias
2021
Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients
Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsReproductive-age womenEtonogestrel contraceptive implantContraceptive implant usersTransplant recipientsContraceptive implantsCommon transplant-related complicationPost-transplant infectionsSafe contraceptive optionTransplant-related outcomesRetrospective cohort studyTransplant-related complicationsGraft-related complicationsSide effect profileTertiary medical centerRisk of pregnancyImplant usersContraceptive implant useAdditional health risksPregnancy patternsCohort studyGraft complicationsGraft rejectionEffect profileAn exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users
Lazorwitz A, Sheeder J, Teal S. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users. The European Journal Of Contraception & Reproductive Health Care 2021, 26: 323-325. PMID: 33596152, PMCID: PMC8496990, DOI: 10.1080/13625187.2021.1887475.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsExercise habitsImplant usersStanford Brief Activity SurveySteady-state pharmacokineticsReproductive-age womenLiquid chromatography-mass spectrometry assayEtonogestrel implantsLifestyle factorsSedentary lifestyleMass spectrometry assaySecondary analysisSignificant associationVital signsActivity SurveyDietAssociationExploratory studyInconsistent effectsHabitsParticipantsPharmacokineticsSurvey responses
2020
A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Seale R, Davis A, Guiahi M. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception 2020, 102: 58-60. PMID: 32325076, PMCID: PMC7272275, DOI: 10.1016/j.contraception.2020.04.011.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsReproductive-age womenOvulatory suppressionContraceptive implantsImplant usersHealthy reproductive-age womenEffect of isotretinoinEtonogestrel contraceptive implantIsotretinoin therapyPharmacokinetic interactionsReliable contraceptionIsotretinoinSmall studyPilot studyPotent teratogenBaselineWomenSignificant changesAppropriate optionImplantsEtonogestrelPatientsPregnancy
2019
Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersBody mass indexBlack/African American raceEtonogestrel concentrationsAfrican American raceMass indexPatient characteristicsImplant useEtonogestrel levelsImplant usersAmerican raceHispanic/Latina ethnicityMedian body mass indexSerum etonogestrel levelsEtonogestrel contraceptive implantSide effect profileReproductive-age womenCertain patient characteristicsIndividual patient characteristicsMajority of womenNon-significant increaseLatina ethnicityMedian ageSerum concentrationsInfluence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A, Aquilante C, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2019, 133: 783-794. PMID: 30870275, PMCID: PMC6448146, DOI: 10.1097/aog.0000000000003189.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsBody mass indexContraceptive implant usersEtonogestrel concentrationsSteroid hormone metabolismImplant useGenetic variantsHepatic enzyme inducersReproductive-age womenImplant usersHormone metabolismPersonalized medicine approachVariant allele frequencyOvulatory suppressionEtonogestrel implantsMass indexHormonal contraceptionConcomitant useWomen's healthPg/Medicine approachParticipant characteristicsSteroid hormonesEnzyme inducersPharmacogenomic investigations
2017
The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception 2017, 95: 571-577. PMID: 28288788, DOI: 10.1016/j.contraception.2017.03.004.Peer-Reviewed Original ResearchConceptsEtonogestrel concentrationsEtonogestrel contraceptive implantCarbamazepine coadministrationFollicle-like structuresOvulatory suppressionEndometrial thicknessMean ageContraceptive implantsPg/Contraceptive implant usersEtonogestrel implant usersSerum etonogestrel concentrationsReproductive-age womenBody mass indexRisk of pregnancyEffects of carbamazepineImplant usersParticipants' mean ageImpact of carbamazepineEtonogestrel levelsMedian durationPharmacodynamic changesTransvaginal ultrasoundMajority of participantsMass index